1. N 6 -cyclohexyladenosine is better than meperidine and buspirone at suppressing metabolism during TTM32 but does not improve outcome after cardiac arrest.
- Author
-
Laughlin BW, Sugiura MH, Jenkins M, Chen CY, and Drew KL
- Subjects
- Animals, Rats, Male, Heart Rate drug effects, Blood Pressure drug effects, Theophylline analogs & derivatives, Theophylline pharmacology, Theophylline therapeutic use, Treatment Outcome, Adenosine analogs & derivatives, Adenosine pharmacology, Buspirone pharmacology, Buspirone therapeutic use, Heart Arrest drug therapy, Rats, Sprague-Dawley, Meperidine pharmacology, Meperidine analogs & derivatives, Meperidine therapeutic use
- Abstract
N
6 -clyclohexyladenosine (CHA) is an adenosine A1 receptor agonist that inhibits thermogenesis. Cardiovascular side effects however, limit use of CHA as a therapeutic. We and others have shown that this can be reversed by administering 8-p-(sulfophenyl)theophylline (8-SPT), a nonspecific antagonist that does not cross the BBB. Other evidence shows that CNS actions of CHA may contribute to bradycardia through enhanced vagal tone and other mechanisms. Here we test the hypothesis that 8-SPT pretreatment alone is sufficient to prevent hypotension caused by CHA. To test this hypothesis, we pretreated rats with 8-SPT alone, and in combination with other antagonists to test the hypothesis that direct action of CHA on the heart is the primary mechanism by which CHA induces bradycardia and hypotension. Results show that pretreatment with 8-SPT alone is not sufficient to prevent CHA-induced hypotension. Pretreatment with 8-SPT or atropine alone did not prevent the fall in mean arterial pressure (MAP) and heart rate (HR), however, pretreatment with 8-SPT (25 mg/kg) and atropine (1 mg/kg) 15 min before CHA (1 mg/kg) preserves MAP and HR baseline values after CHA administration. We next asked if blood pressure was managed during the transition into a hypometabolic state, would prolong CHA-mediated inhibition of metabolism after cardiac arrest improve outcome better than anti-shivering medications meperidine and buspirone. We found that CHA-mediated hypotension can be mitigated by pretreatment with atropine and 8-SPT. This combination administered after cardiac arrest facilitated temperature management and metabolic suppression better than meperidine and buspirone, however, did not improve survival., Competing Interests: Declaration of competing interest Kelly Drew has a financial interest in Be Cool Pharmaceutics. Kelly Drew and Bernard Laughlin hold intellectual property for technology related to formulation. For other authors the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024. Published by Elsevier Inc.) more...- Published
- 2024
- Full Text
- View/download PDF